Testosterone undecanoate combined with depomedroxyprogesterone acetate in two month intervals in Asian men

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN31330564

Enrollment

Registered

2004-04-01

Start date

2003-06-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Male contraception Pregnancy and Childbirth Male contraception

Interventions

1. 500 mg TU and 150 mg DMPA injected at eight week intervals (n = up to 32) 2. 500 mg TU and 250 mg DMPA injected at eight week intervals (n = up to 32)

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: 1. Men in good health, aged 20 to 45 2. No desire for children for next 15 months 3. Normal reproductive state: a. sperm concentrations greater than or equal to 20 million/ml b. sperm motility greater than 50% (rapid and slow progressive) or grade a greater than 15% c. morphology greater than 15% normal forms using the World Health Organisation (WHO) strict criteria, or d. within the normal range for the centre 4. Body mass index between 20 and 29 kg/m^2

Exclusion criteria

Exclusion criteria: No exclusion criteria

Design outcomes

Primary

Measure	Time frame
1. Changes in sperm concentrations to azoospermia or severe oligozoospermia at 24 weeks 2. Time to suppress spermatogenesis at 24 weeks	—

Secondary

Measure	Time frame
Suppression of gonadotropins and maintenance of normal blood testosterone levels at 24 weeks.	—

Countries

China, India, Indonesia

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026